Estate of Patricia Benigni v. Samir Alsawah Md

CourtMichigan Court of Appeals
DecidedApril 15, 2025
Docket369109
StatusUnpublished

This text of Estate of Patricia Benigni v. Samir Alsawah Md (Estate of Patricia Benigni v. Samir Alsawah Md) is published on Counsel Stack Legal Research, covering Michigan Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Estate of Patricia Benigni v. Samir Alsawah Md, (Mich. Ct. App. 2025).

Opinion

If this opinion indicates that it is “FOR PUBLICATION,” it is subject to revision until final publication in the Michigan Appeals Reports.

STATE OF MICHIGAN

COURT OF APPEALS

MICHAEL BENIGNI, Personal Representative of UNPUBLISHED the ESTATE OF PATRICIA BENIGNI, April 15, 2025 10:27 AM Plaintiff-Appellant,

v No. 369109 St. Clair Circuit Court SAMIR ALSAWAH, M.D., and HURON LC No. 19-001198-NH MEDICAL CENTER, PC,

Defendants-Appellees.

Before: MALDONADO, P.J., and LETICA and WALLACE, JJ.

PER CURIAM.

In this traditional medical malpractice action, plaintiff, Michael Benigni, as the personal representative of the Estate of Patricia Benigni, appeals as of right the trial court order granting summary disposition in favor of defendants, Samir Alsawah, M.D., and Huron Medical Center, P.C. We affirm.

I. FACTUAL AND PROCEDURAL HISTORY

This case was the subject of a prior appeal. In Benigni v Alsawah, 343 Mich App 200, 203- 204; 996 NW2d 821 (2022),1 this Court set forth the following factual history:

In 2012, Patricia was diagnosed with Stage III colorectal cancer. She was referred to HMC and Dr. Alsawah, a board-certified medical oncologist, in November 2012. Patricia received neoadjuvant chemotherapy and radiation treatment to prepare for surgery. Subsequently, a resection to remove the tumor was performed in February 2013. From March to September 2013, Patricia received nine rounds of adjuvant chemotherapy to lower the risk of recurrence and to address lymph node concerns. Throughout 2013, Dr. Alsawah checked and

1 The Benigni decision was rendered by a majority and a dissent.

-1- monitored Patricia’s carcinoembryonic antigen (CEA) level approximately every four to six weeks, with the level ranging from 1.6 to 4.4 nanograms per milliliter of blood (ng/mL) in nine separate tests. An abdominal and pelvic computerized tomography (CT) scan did not reveal recurrence or spread of the cancer.

Monitoring CEA levels in patients is a critical indicator for discovering cancer recurrence. In his deposition, Dr. Jeffrey Gordon, a board-certified medical oncologist and hematologist, testified that based on his experience and review of peer-reviewed medical literature, a CEA level above 15 ng/mL rarely reflected a false indicator of colorectal cancer. And, according to Dr. Gordon, if the CEA level was over 35 ng/mL, “it was always associated with a recurrence of colorectal cancer.”

In March 2014, Patricia’s CEA level was checked again, and it measured 4.5 ng/mL. This was the only CEA test performed in 2014. Patricia’s CEA level was 8.3 ng/mL in January 2015 and rose to 24.2 ng/mL in April 2015. By November 2015, her CEA level had once again risen, testing at 38.6 ng/mL. Despite Patricia’s elevated CEA level, a CT scan performed in 2015 did not reveal a recurrence or spread of the cancer. Dr. Alsawah did not order any other diagnostic procedures or further explore the cause of the elevated CEA level.

For the next two years, Patricia’s CEA levels continued to rise precipitously. Patricia had a CEA level of 59.3 ng/mL in May 2016. A CT scan and colonoscopy were performed but did not reveal a recurrence or metastasis of the cancer. When Patricia saw Dr. Alsawah on August 23, 2016, he again tested her CEA level, which measured 78.5 ng/mL. She also complained of fatigue. Again, Dr. Alsawah did not further explore the cause of the elevated CEA level. He also began scheduling Patricia for visits every six months.

In February 2017, Patricia’s CEA level was 175.9 ng/mL. In August 2017, her CEA level measured 459 ng/mL, and Patricia complained of weakness and fatigue. A CT scan performed in August 2017 revealed a large liver mass suspicious of metastasis[2] with possible involvement of the adrenal glands. There was no apparent indication of tumor recurrence at the original surgical site. A positron emission tomography (PET) scan also showed a large hepatic mass and additionally gave rise to cancer concerns regarding the right adrenal gland. Patricia had a liver biopsy on October 9, 2017, which confirmed a metastatic adenocarcinoma.

2 “Metastasis is when cancer spreads beyond the place where it started to other areas of your body. Nearly all cancers have the potential to metastasize.” (accessed April 14, 2025).

-2- On October 23, 2017, Patricia conferred with a surgeon regarding possible treatment of the metastasized cancer but was advised that surgery was no longer a viable option. Patricia died in February 2018.

The Benigni majority then summarized the complaint and set forth the allegations of malpractice raised by plaintiff, the Estate:

On May 24, 2019, the Estate filed a medical malpractice complaint against HMC and Dr. Alsawah. Count I alleged negligence by Dr. Alsawah. The Estate maintained that Dr. Alsawah breached the standard of care by failing to “[e]valuate and/or investigate the cause of [Patricia’s] increasing CEA levels[,]” by failing to “[w]ork up the patient to rule out the presence of metastatic disease[,]” and by committing “[o]ther acts and/or omissions to be determined throughout the course of discovery.” The Estate also alleged:

34. As a direct and proximate result of the aforementioned violations of the standard of care by Dr. Alsawah, there was a delay in the diagnosis of Patricia Benigni’s metastatic disease.

35. As a result of the delay in diagnosis, there was an advancement in the disease process resulting in the formation of metastatic lesions in the liver and adrenal glands.

36. That an earlier diagnosis of the disease would have given Patricia Benigni a better prognosis, including increased survival or cure.

In Count II of the complaint, the Estate alleged vicarious liability with respect to HMC.

The Estate attached to the complaint an affidavit of merit by Dr. Gordon. He averred that “[a]n earlier diagnosis of the disease would have given Patricia Benigni a better prognosis, including survival.” [Id. at 205-206.]

In February 2021, defendants moved for summary disposition under MCR 2.116(C)(10), relying on the loss-of-opportunity doctrine. Defendants contended that there was no scientifically reliable information to establish that Patricia’s opportunity to survive “was ever greater than 50% or that her opportunity to survive was diminished by 50%.” To support this claim, defendants claimed that cancer treatment community literature established that Patricia’s opportunity to survive “was not reduced by greater than 50% as a result of the alleged delay in diagnosing the metastasis.” Id. at 208.

The Estate countered that defendants ignored the spirit of the lost-opportunity doctrine which allowed for recovery of the loss of an opportunity to survive, not merely the initial opportunity to survive. The Estate alleged that a proper evaluation and treatment of Patricia’s CEA levels would have resulted in an earlier diagnosis, “curative treatment options” and increased her opportunity to survive or to achieve a better result. The trial court issued a written opinion granting the defendants’ motion. It noted that the parties agreed that the controlling analysis was

-3- found in Fulton v William Beaumont Hosp, 253 Mich App 70, 84; 655 NW2d 569 (2002), and accepted that it was a lost-opportunity case. The trial court ultimately granted summary disposition to defendants, concluding that there was no evidence “that Patricia’s opportunity to survive was reduced by 50% as a result of Dr. Alsawah’s alleged malpractice[.]” Benigni, 343 Mich App at 209.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

O’neal v. St John Hospital & Medical Center
791 N.W.2d 853 (Michigan Supreme Court, 2010)
Fulton v. William Beaumont Hospital
655 N.W.2d 569 (Michigan Court of Appeals, 2002)
Quinto v. Cross and Peters Co.
547 N.W.2d 314 (Michigan Supreme Court, 1996)
Skinner v. Square D Co.
516 N.W.2d 475 (Michigan Supreme Court, 1994)
Weymers v. Khera
563 N.W.2d 647 (Michigan Supreme Court, 1997)
Badalamenti v. William Beaumont Hospital-Troy
602 N.W.2d 854 (Michigan Court of Appeals, 1999)
Teal v. Prasad
772 N.W.2d 57 (Michigan Court of Appeals, 2009)
Craig v. Oakwood Hospital
684 N.W.2d 296 (Michigan Supreme Court, 2004)
Elher v. Misra
878 N.W.2d 790 (Michigan Supreme Court, 2016)
Decker v. Rochowiak
287 Mich. App. 666 (Michigan Court of Appeals, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Estate of Patricia Benigni v. Samir Alsawah Md, Counsel Stack Legal Research, https://law.counselstack.com/opinion/estate-of-patricia-benigni-v-samir-alsawah-md-michctapp-2025.